These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 10084288

  • 1. Strategies for iron supplementation: oral versus intravenous.
    Macdougall IC.
    Kidney Int Suppl; 1999 Mar; 69():S61-6. PubMed ID: 10084288
    [Abstract] [Full Text] [Related]

  • 2. Iron status and iron supplementation in peritoneal dialysis patients.
    Vychytil A, Haag-Weber M.
    Kidney Int Suppl; 1999 Mar; 69():S71-8. PubMed ID: 10084290
    [Abstract] [Full Text] [Related]

  • 3. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
    Tarng DC, Huang TP, Chen TW, Yang WC.
    Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
    [Abstract] [Full Text] [Related]

  • 4. Iron monitoring and supplementation: how do we achieve the best results?
    Schaefer RM, Schaefer L.
    Nephrol Dial Transplant; 1998 Mar; 13 Suppl 2():9-12. PubMed ID: 9566484
    [Abstract] [Full Text] [Related]

  • 5. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL, Johnson CA.
    Am J Health Syst Pharm; 2002 Mar 01; 59(5):429-35. PubMed ID: 11887409
    [Abstract] [Full Text] [Related]

  • 6. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
    Johnson CA, Rosowski E, Zimmerman SW.
    Adv Perit Dial; 1992 Mar 01; 8():444-7. PubMed ID: 1361844
    [Abstract] [Full Text] [Related]

  • 7. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D, Johnson CA, Wish JB, Rocco MV, Madore F, Owen WF.
    Kidney Int; 2000 Feb 01; 57(2):578-89. PubMed ID: 10652035
    [Abstract] [Full Text] [Related]

  • 8. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
    Taylor JE, Peat N, Porter C, Morgan AG.
    Nephrol Dial Transplant; 1996 Jun 01; 11(6):1079-83. PubMed ID: 8671972
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic value of iron indices in hemodialysis patients receiving epoetin.
    Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA, Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kidney Int; 2001 Jul 01; 60(1):300-8. PubMed ID: 11422765
    [Abstract] [Full Text] [Related]

  • 10. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK, Morgenstern T.
    Dtsch Med Wochenschr; 2004 Sep 03; 129(36):1849-53. PubMed ID: 15368155
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.
    Wingard RL, Parker RA, Ismail N, Hakim RM.
    Am J Kidney Dis; 1995 Mar 03; 25(3):433-9. PubMed ID: 7872321
    [Abstract] [Full Text] [Related]

  • 12. Intravenous iron for the treatment of predialysis anemia.
    Silverberg DS, Blum M, Agbaria Z, Schwartz D, Zubkov A, Yachnin T, Iaina A.
    Kidney Int Suppl; 1999 Mar 03; 69():S79-85. PubMed ID: 10084291
    [Abstract] [Full Text] [Related]

  • 13. Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients.
    Greenbaum LA, Pan CG, Caley C, Nelson T, Sheth KJ.
    Pediatr Nephrol; 2000 Sep 03; 14(10-11):908-11. PubMed ID: 10975297
    [Abstract] [Full Text] [Related]

  • 14. Considerations for optimal iron use for anemia due to chronic kidney disease.
    Hudson JQ, Comstock TJ.
    Clin Ther; 2001 Oct 03; 23(10):1637-71. PubMed ID: 11726002
    [Abstract] [Full Text] [Related]

  • 15. Safety of intravenous injection of iron saccharate in haemodialysis patients.
    Sunder-Plassmann G, Hörl WH.
    Nephrol Dial Transplant; 1996 Sep 03; 11(9):1797-802. PubMed ID: 8918625
    [Abstract] [Full Text] [Related]

  • 16. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.
    Nissenson AR, Berns JS, Sakiewicz P, Ghaddar S, Moore GM, Schleicher RB, Seligman PA.
    Am J Kidney Dis; 2003 Aug 03; 42(2):325-30. PubMed ID: 12900815
    [Abstract] [Full Text] [Related]

  • 17. The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy.
    Schaefer RM, Schaefer L.
    J Perinat Med; 1995 Aug 03; 23(1-2):83-8. PubMed ID: 7658326
    [Abstract] [Full Text] [Related]

  • 18. Serial ferritin concentrations in hemodialysis patients receiving intravenous iron.
    Kirschbaum B.
    Clin Nephrol; 2002 Jun 03; 57(6):452-6. PubMed ID: 12078949
    [Abstract] [Full Text] [Related]

  • 19. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ.
    Am J Nephrol; 2000 Jun 03; 20(6):455-62. PubMed ID: 11146312
    [Abstract] [Full Text] [Related]

  • 20. A comprehensive vision for intravenous iron therapy.
    Coyne DW.
    Am J Kidney Dis; 2008 Dec 03; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.